Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syncom Formulation (India)BOM:524470 +0.51%87 Current Ratio is 3.18 as of Mar. 2026, which is 45% above its 10-year median of 2.19. GuruFocus rates BOM:524470 with a GF Score™ of 87/100 and a GF Value™ of ₹19.99 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,000 Drug Manufacturers companies, Syncom Formulation (India) ranks better than 69.4% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Syncom Formulation (India)'s current ratio for the quarter that ended in Mar. 2026 was 3.18.
Syncom Formulation (India) has a current ratio of 3.18. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Syncom Formulation (India)'s Current Ratio or its related term are showing as below:
BOM:524470'
s Current Ratio Range Over the Past 10 Years
Min: 1.57 Med: 2.19 Max: 4.55
Current: 3.18
During the past 13 years, Syncom Formulation (India)'s highest Current Ratio was 4.55. The lowest was 1.57. And the median was 2.19.
BOM:524470's Current Ratio is ranked better than 69.4% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 2
vs BOM:524470: 3.18
Syncom Formulation (India) (BOM:524470) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Syncom Formulation (India) Current Ratio Related Terms
Syncom Formulation (India) Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syncom Formulation (India) Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Current Ratio distribution charts can be found below:
* The bar in red indicates where Syncom Formulation (India)'s Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syncom Formulation (India) (BOM:524470) has a Current Ratio of 3.18 as of Mar. 2026. This is 45% above median its historical median of 2.19. Over the past decade, Syncom Formulation (India)'s Current Ratio has ranged from 1.57 to 4.55. According to the industry distribution chart, Syncom Formulation (India) ranks #306 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 30.6%.
Is Syncom Formulation (India)'s Current Ratio too high?
Syncom Formulation (India)'s current Current Ratio of 3.18 is 45% above median its 10-year median of 2.19. Over the past 10 years, this metric has ranged from a low of 1.57 to a high of 4.55. The Drug Manufacturers industry median Current Ratio is 2.00. Syncom Formulation (India)'s value of 3.18 is 59% above this industry median. Based on the distribution chart, Syncom Formulation (India) ranks #306 out of 1000 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Syncom Formulation (India) has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syncom Formulation (India)'s Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Syncom Formulation (India) ranks #306 out of 1000 companies for Current Ratio. This puts Syncom Formulation (India) in the upper half of its industry. The industry median Current Ratio is 2.00. Syncom Formulation (India)'s value of 3.18 is 59% above this benchmark. Historically, Syncom Formulation (India)'s own Current Ratio has ranged from 1.57 to 4.55 over the past decade. While the company's 10-year median is 2.19 vs. the industry median of 2.00, Syncom Formulation (India) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syncom Formulation (India)'s current Current Ratio of 3.18 is 59% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syncom Formulation (India)'s current Current Ratio is 3.18, which is 45% above median its own 10-year median of 2.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syncom Formulation (India) stock overvalued right now?
Based on GuruFocus' analysis, Syncom Formulation (India) (BOM:524470) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹19.99, compared to a current price of ₹13.83 — trading 30.8% below its estimated fair value. The current Current Ratio is 3.18, which is 45% above median its 10-year median of 2.19 and 59% above the Drug Manufacturers industry median of 2.00. Syncom Formulation (India)'s overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Syncom Formulation (India) (BOM:524470), the current Current Ratio is 3.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syncom Formulation (India) (BOM:524470) Overvalued in 2026?
Based on GuruFocus' analysis, Syncom Formulation (India) stock appears to be undervalued.
The current stock price of ₹13.83 is trading 30.8% below its estimated GF Value™ of ₹19.99.
GuruFocus considers Syncom Formulation (India) to be Significantly Undervalued.
Key valuation signals for BOM:524470:
Current Ratio: 3.18 (45% above median its 10-year median of 2.19)
GF Value™: ₹19.99 vs. price of ₹13.83 (30.8% below fair value)
Industry Position: 59% above the Drug Manufacturers median (#306 of 1000)
No single metric tells the full story. See the BOM:524470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
87GF Score
Get the complete analysis for BOM:524470
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524470 has been successfully added to your 
